Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance

Table 3 CMR characteristics of Fabry disease patients divided into LVH positive/LVH negative and Healthy volunteers

	Healthy volunteers (n = 63)	FD LVH negative (n = 25)	FD LVH positive (n = 38)	p-value^†
LV Mass i (g/m2)	66 ± 14	72 ± 13	132 ± 46	<0.01
Max wall thickness (mm)		8 ± 2	16 ± 4	<0.01
LVEDVi (ml/m2)	72 ± 13	70 ± 15	67 ± 16	0.30
LVESVi (ml/m2)	24 ± 7	17 ± 6	16 ± 6	0.10
LVEF (%)	67 ± 5	74 ± 6	78 ± 7	0.05
Left atrial area i (cm2/m2)	11 ± 2	12 ± 3	13 ± 3	0.03
LGE	0	4(17)	26(79)	<0.01
infero-lateral wall		4(17)	25(76)	<0.01
extensive		0	2(6)
RV inserction points		0	1(3)
Average septal T1 (ms)*	968 ± 32	904 ± 46	853 ± 50	<0.01
Average infero-lateral T1 (ms)*		894 ± 65	903 ± 45	0.27
Average infero-lateral T1 (ms)*
LGE yes		954 ± 15	919 ± 63	0.01
LGE no		888 ± 41	848 ± 32	<0.01

Data are expressed as n (percentage) or mean ± standard deviation.
*native T1 measured by ShMOLLI sequences.
^†p value between LVH negative and LVH positive groups.
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; LGE: late gadolinium enhancement; LVEF: left ventricular ejection fraction, RV: right ventricle.

ISSN: 1532-429X